Search results for "Repair"

showing 10 items of 747 documents

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

2010

Abstract Purpose: Quantitative methylation-specific tests suggest that not all cells in a glioblastoma with detectable promoter methylation of the O6-methylguanine DNA methyltransferase (MGMT) gene carry a methylated MGMT allele. This observation may indicate cell subpopulations with distinct MGMT status, raising the question of the clinically relevant cutoff of MGMT methylation therapy. Epigenetic silencing of the MGMT gene by promoter methylation blunts repair of O6-methyl guanine and has been shown to be a predictive factor for benefit from alkylating agent therapy in glioblastoma. Experimental Design: Ten paired samples of glioblastoma and respective glioblastoma-derived spheres (GS), c…

AdultMaleCancer ResearchMethyltransferaseDNA repairBiologyDNA methyltransferaseGene dosageO(6)-Methylguanine-DNA MethyltransferaseGene FrequencyTumor Cells CulturedHumansPromoter Regions GeneticneoplasmsAgedAged 80 and overBrain NeoplasmsO-6-methylguanine-DNA methyltransferaseMethylationDNA MethylationMiddle AgedMolecular biologydigestive system diseasesChromatinOncologyCpG siteDNA methylationFemaleGlioblastomaClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Loss of SMARCB1 expression in colon carcinoma

2020

International audience; SMARCB1 is a tumor suppressor gene, which is part of SWI/SNF complex involved in transcriptional regulation. Recently, loss of SMARCB1 expression has been reported in gastrointestinal carcinomas. Our purpose was to evaluate the incidence and prognostic value of SMARCB1 loss in colon carcinoma (CC). Patients with stage III CC (n = 1695), and a second cohort of 23 patients with poorly differentiated CC were analyzed. Immunohistochemistry for SMARCB1 was performed on tissue microarrays, and cases with loss of expression were controlled on whole sections. Loss of SMARCB1 was compared with the clinico-pathological and molecular characteristics, and the prognostic value wa…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyMedullary cavityTumor suppressor geneSMARCB1[SDV.CAN]Life Sciences [q-bio]/Cancercolon carcinomaYoung AdultGeneticsmedicineHumans0501 psychology and cognitive sciencesStage (cooking)SMARCB1AgedNeoplasm Staging0505 lawTissue microarrayBRAF V600Emismatch repair deficiencybusiness.industry05 social sciencesHistologySMARCB1 ProteinGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistry3. Good healthOncologyMedullary carcinomaColonic Neoplasms050501 criminologyImmunohistochemistryFemalebusiness050104 developmental & child psychologyCancer Biomarkers
researchProduct

O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.

1995

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is a main determinant of resistance of tumor cells to the cytostatic activity of chemotherapeutic alkylating agents (methylating and chloroethylating nitrosoureas) and is effective in protecting normal cells against genotoxic and carcinogenic effects resulting from DNA alkylation. Therefore, the level of expression of MGMT is significant for the response of both the tumor and the non-target tissue following application of nitrosoureas in tumor therapy. To determine the expression of MGMT in tumor tissue, we have assayed MGMT activity in 68 breast carcinomas and 38 brain tumors. There was a wide variation of MGMT expression…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyMethyltransferaseDNA RepairMammary glandBlotting WesternBreast NeoplasmsBiologyAstrocytomaO(6)-Methylguanine-DNA MethyltransferaseGliomaDNA Repair ProteinmedicineCarcinomaHumansneoplasmsCarcinogenAgedEpitheliomaL-Lactate DehydrogenaseBrain NeoplasmsAstrocytomaMethyltransferasesMiddle Agedmedicine.diseasedigestive system diseasesmedicine.anatomical_structureOncologyCancer researchFemaleGlioblastomaHeLa CellsInternational journal of cancer
researchProduct

Increasing rates of DNA single-strand breaks in lymphocytes of clinical personnel handling cytostatic drugs

1993

A total of 27 persons, working in cancer stations with exposure to cytostatics, and 40 healthy control persons were examined for DNA single-strand breaks in peripheral lymphocytes. Non-smoking personnel from cancer stations were found to have an increased rate of DNA single-strand breaks compared to the non-smoking control subjects. In the case of smokers an increased rate of DNA single-strand breaks could be recorded for those working in cancer stations as well as with the controls. DNA single-strand breaks indicate reversible damage to DNA. As DNA repair is not perfect in every case, an increased number of DNA single-strand breaks leads to irreversible DNA damage.

AdultMaleCancer Researchmedicine.medical_specialtyDNA damageDNA repairLymphocyteDNA Single-StrandedAntineoplastic AgentsBiologyMedical Oncologychemistry.chemical_compoundInternal medicinemedicineHumansLymphocytesGeneticsDNA single strandHematologyCancerGeneral MedicineMiddle Agedmedicine.diseasePersonnel Hospitalmedicine.anatomical_structureOncologychemistryToxicityCancer researchFemaleDNADNA DamageJournal of Cancer Research and Clinical Oncology
researchProduct

Occupational exposure to metal-rich particulate matter modifies the expression of repair genes in foundry workers

2021

Foundry workers are exposed to numerous occupational health hazards, which may result in increased risk of cancer, respiratory disease, and other diseases. Oxidative stress is known to be involved in the pathogenesis of such diseases. The present study aimed to investigate the association between multiple occupational exposures in foundry workers and expression of deoxyribonucleic acid (DNA) repair genes as a biomarker of oxidative DNA damage. The study sample comprised 17 foundry workers and 27 matched control subjects. Expression of 8-oxoguanine DNA glycosylase-1 (OGG1), inosine triphosphate pyrophosphate (ITPA), and MutT homolog 1 (MTH1) in peripheral blood was examined using the real-t…

AdultMaleDNA repairThreshold limit valueHealth Toxicology and MutagenesisIran010501 environmental sciencesToxicologymedicine.disease_cause01 natural sciencesDNA Glycosylaseslaw.invention03 medical and health sciencesElectromagnetic FieldslawMetals HeavyOccupational ExposureHumansMedicinePyrophosphatasesGenePolymerase chain reaction030304 developmental biology0105 earth and related environmental sciences0303 health sciencesbusiness.industryPublic Health Environmental and Occupational HealthMiddle AgedPhosphoric Monoester HydrolasesOxidative StressDNA Repair EnzymesCase-Control StudiesMetallurgyImmunologyToxicityBiomarker (medicine)Particulate MatterITPAbusinessBiomarkersOxidative stressDNA DamageToxicology and Industrial Health
researchProduct

Gray matter network reorganization in multiple sclerosis from 7‐Tesla and 3‐Tesla MRI data

2020

[Objective]: The objective of this study was to determine the ability of 7T‐MRI for characterizing brain tissue integrity in early relapsing‐remitting MS patients compared to conventional 3T‐MRI and to investigate whether 7T‐MRI improves the performance for detecting cortical gray matter neurodegeneration and its associated network reorganization dynamics.

AdultMaleDYNAMICS0301 basic medicineNeurosciences. Biological psychiatry. NeuropsychiatryBrain tissueATROPHYYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineText miningAtrophymedicineHumans3 TGray MatterRC346-429Research ArticlesCerebral CortexCHALLENGESbusiness.industryDISABILITYGeneral NeuroscienceMultiple sclerosisMiddle AgedTissue repairmedicine.diseaseMagnetic Resonance ImagingWhite Matter030104 developmental biologyHealthy individualsFemaleNeurology. Diseases of the nervous systemNeurology (clinical)Nerve NetbusinessNuclear medicine030217 neurology & neurosurgeryRC321-571Research ArticleAnnals of Clinical and Translational Neurology
researchProduct

Long-time expression of DNA repair enzymes MGMT and APE in human peripheral blood mononuclear cells.

2001

The DNA repair enzymes O6-methylguanine-DNA methyltransferase (MGMT) and apurinic/apyrimidinic endonuclease (APE, also known as Ref-1) play an important role in cellular defense against the mutagenic and carcinogenic effects of DNA-damaging agents. Cells with low enzyme activity are more sensitive to induced DNA damage and may confer a higher carcinogenic risk to the individuals in question. To study the level of variability of MGMT and APE expression in human, we analyzed in a long-time study MGMT and APE expression in peripheral blood mononuclear cells (PBMC) from healthy individuals. The data revealed high inter- and intraindividual variability of MGMT but not of APE. For MGMT, the inter…

AdultMaleMethyltransferaseTime FactorsDNA LigasesDNA repairDNA damageHealth Toxicology and MutagenesisBlotting WesternCarbon-Oxygen LyasesBiologyToxicologyPeripheral blood mononuclear cellMonocytesEndonucleaseO(6)-Methylguanine-DNA MethyltransferaseGene expressionDNA-(Apurinic or Apyrimidinic Site) LyaseHumansneoplasmsCarcinogenSmokingGeneral MedicineDNA-(apurinic or apyrimidinic site) lyaseMolecular biologydigestive system diseasesDeoxyribonuclease IV (Phage T4-Induced)biology.proteinFemaleArchives of toxicology
researchProduct

Collagen ultrastructure in ruptured cruciate ligaments

1992

The ultrastructure of collagen fibrils was investigated in normal (n 39) and ruptured (n 23) human anterior cruciate ligaments. The normal ligament had a complex three-dimensional structure. Collagen fibrils predominantly had a unidirectional course with parallel arrangement and a mean diameter of 75 (20-185) nm. Four days after anterior cruciate ligament rupture, the mean fibril diameter was increased; it later decreased, probably due to synthesis of young, thin 30-40 nm fibrils. Interfibrillar dysplastic collagen fibrils were detected in the extracellular matrix of ruptured ligaments. They were more frequently found later than 3 days after rupture and were seen also at a distance of 2-3 c…

AdultMaleMicroscopy Electron Scanning TransmissionPathologymedicine.medical_specialtyTime FactorsAdolescentAnterior cruciate ligamentmacromolecular substancesFibrillaw.inventionExtracellular matrixlawmedicineHumansOrthopedics and Sports MedicineElectron microscopicRupturebusiness.industryAnterior Cruciate Ligament InjuriesAnatomyMiddle Agedmedicine.anatomical_structureRepair tissueEvaluation Studies as TopicMicroscopy Electron ScanningUltrastructureLigamentWounds and InjuriesFemaleSurgeryCollagenElectron microscopebusinessActa Orthopaedica Scandinavica
researchProduct

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004

Abstract Purpose: No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic non-small cell lung cancer (NSCLC); however, the selection of patients according to key genetic characteristics can help to tailor chemotherapy. Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Experimental Design: Patients were part of a large randomized trial carried out from September 1998 to July 2000, comparing gemcitabine/cisplatin versus gemcit…

AdultMaleOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsDNA RepairRibonucleoside Diphosphate Reductasemedicine.medical_treatmentAntineoplastic AgentsBiologyVinorelbineDeoxycytidineCarcinoma Non-Small-Cell LungInternal medicineRibonucleotide ReductasesmedicineHumansRNA MessengerLung cancerAgedCisplatinChemotherapyPredictive markerTumor Suppressor ProteinsDNAMiddle AgedEndonucleasesPrognosismedicine.diseaseGemcitabineChemotherapy regimenGemcitabineDNA-Binding ProteinsTreatment OutcomeOncologyFemaleCisplatinERCC1medicine.drugClinical Cancer Research
researchProduct

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

2009

Purpose To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. Patients and Methods A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m 2 (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m 2 ), maintenance TMZ starting at 150 mg/m 2 using a 1-week on/1-week off schedule, plus maintenance indomethacin (25 mg twice daily). Results The median follow-up interval was 21.7 months. Grade 4 hematologic toxicit…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentIndomethacinDisease-Free SurvivalDrug Administration ScheduleGermanyInternal medicineConfidence IntervalsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesKarnofsky Performance StatusAntineoplastic Agents AlkylatingDNA Modification MethylasesSurvival rateAgedChemotherapyRadiationTemozolomideBrain Neoplasmsbusiness.industryTumor Suppressor ProteinsAnti-Inflammatory Agents Non-SteroidalDNA MethylationMiddle AgedCombined Modality TherapyConfidence intervalSurgeryDacarbazineSurvival RateRegimenDNA Repair EnzymesOncologyConcomitantToxicityFemaleGlioblastomabusinessChemoradiotherapyFollow-Up Studiesmedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct